Indication
Plasma Cell Neoplasm
5 clinical trials
13 products
1 drug
Clinical trial
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2024-12-30
Product
COM902Product
COM902 + COM701Product
COM902 (RDFE)Clinical trial
Influenza Vaccination in Plasma Cell DyscrasiasStatus: Completed, Estimated PCD: 2021-05-11
Product
Trivalent Influenza VaccineClinical trial
Phase I Dose Escalation of T-cell Receptor α/β Depleted Donor Lymphocyte Infusions Following CD34+- Selected Allogeneic Stem Cell Transplantation From Related & Unrelated Donors in Patients With Lymphoid, Myeloid or Plasma Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-12-07
Product
Radiation TherapyClinical trial
Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell TransplantationStatus: Completed
Product
Keyhole limpet hemocyaninProduct
melphalanDrug
sargramostim